Loomis Sayles & Co. L P Cuts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Loomis Sayles & Co. L P cut its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,210,160 shares of the life sciences company's stock after selling 132,580 shares during the period. Illumina comprises 60.8% of Loomis Sayles & Co. L P's portfolio, making the stock its 28th largest holding. Loomis Sayles & Co. L P owned approximately 2.65% of Illumina worth $562,604,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ILMN. Versant Capital Management Inc raised its position in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after buying an additional 146 shares during the last quarter. Golden State Wealth Management LLC purchased a new position in Illumina during the fourth quarter valued at $32,000. Assetmark Inc. increased its holdings in Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Illumina in the 4th quarter worth $45,000. Finally, Lee Danner & Bass Inc. bought a new position in shares of Illumina during the 4th quarter valued at about $48,000. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on ILMN shares. Robert W. Baird decreased their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Canaccord Genuity Group decreased their price objective on Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a report on Tuesday, March 11th. Hsbc Global Res lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and set a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Finally, Royal Bank of Canada lowered their price objective on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a research report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $140.90.

Remove Ads

Illumina Trading Down 2.8 %

ILMN stock traded down $2.28 during midday trading on Friday, reaching $80.00. The company's stock had a trading volume of 1,526,373 shares, compared to its average volume of 2,212,008. The firm has a market capitalization of $12.67 billion, a price-to-earnings ratio of -10.42, a PEG ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 1 year low of $79.30 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock has a fifty day simple moving average of $102.80 and a two-hundred day simple moving average of $126.81.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.